Daiichi Sankyo Daichirona for Intramuscular Injection approved for manufacturing, marketing as booster vaccination in Japan

DAICHIRONA for Intramuscular Injection is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain of the spike protein of the novel coronavirus, utilizing a novel nucleic acid drug delivery system discovered by Daiichi Sankyo.;

Published On 2023-08-02 08:00 GMT | Update On 2023-08-02 08:00 GMT

Tokyo: Daiichi Sankyo has announced that it has received approval for the manufacturing and marketing of DAICHIRONA for Intramuscular Injection (DS-5670), an original monovalent mRNA vaccine against the novel coronavirus infectious disease (hereafter, COVID-19), in Japan for the prevention of infectious disease caused by SARS-CoV-2 (booster vaccination).

The application for approval of DAICHIRONA for its manufacturing and marketing in Japan was submitted in January 2023, and it is now approved as the first Japan-made mRNA vaccine against COVID-19.

DAICHIRONA can be distributed and stored under refrigeration (2°C–8°C), offering improved convenience to healthcare professionals. In the current special temporary vaccination program against COVID-19, Omicron-adapted bivalent mRNA vaccines are used for the booster series campaign that began in May 2023. In addition, the Japanese government has shown an intention to use XBB.1 vaccines for the next booster series campaign that is scheduled to begin in September 2023.

Since DAICHIRONA as approved now is an original monovalent mRNA vaccine for booster series, its supply for the campaign is not planned. However, Daiichi Sankyo will immediately advance the development of an XBB.1-containing monovalent vaccine and strive to supply an XBB.1.5-containing monovalent vaccine before the end of this year at the earliest.

DAICHIRONA for Intramuscular Injection is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus, utilizing a novel nucleic acid drug delivery system discovered by Daiichi Sankyo. The research and development of DAICHIRONA , including the XBB.1.5 monovalent vaccine mentioned in this announcement, is being conducted through the “Vaccine development project” supported by the Japan 2 Agency for Medical Research and Development (AMED) and the “Urgent improvement project for vaccine manufacturing systems” supported by the Japanese Ministry of Health, Labour and Welfare (MHLW).

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Daiichi Sankyo Daichirona for Intramuscular Injection approved for manufacturing, marketing as booster vaccination in Japan

DAICHIRONA for Intramuscular Injection is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain of the spike protein of the novel coronavirus, utilizing a novel nucleic acid drug delivery system discovered by Daiichi Sankyo.;

Similar News

Eli Lilly gets USFDA Breakthrough Therapy designation for olomorasib with Keytruda for lung cancer

NPPA fixes Special Ceiling Price for Gufic's Meropenem Dual Chamber Bags

Sun Pharma Fails to Secure CDSCO Nod for BE, Phase III Waiver on Sitagliptin, Glimepiride, Metformin FDC

USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand Disease

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

Drug Safety Alert: IPC Flags Adverse Reactions linked to Tranexamic acid and Metoclopramide

Virchow Biotech gets CDSCO panel nod to study Semaglutide for chronic weight management

SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies